Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 6/20 | 0.49 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.47 |
| ▸ | TYMP | P19971 | 1/20 | 0.42 |
| ▸ | TK1 | P04183 | 3/20 | 0.42 |
| ▸ | TK2 | O00142 | 3/20 | 0.42 |
| ▸ | TYMS | P04818 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4731659 | 1.00 | TOP2A (0.49) | TOP2ARNASE1TYMPTK1TK2 | |
| SCHEMBL23211681 | 0.92 | RNASE1 (0.46) | TOP2ARNASE1TYMPTK1TK2 | |
| SCHEMBL25400207 | 0.92 | HSP90AA1 (0.47) | TOP2ARNASE1TYMPTYMS | |
| SCHEMBL6830771 | 0.90 | RNASE1 (0.51) | TOP2ARNASE1TYMPTK1TYMS | |
| SCHEMBL8657849 | 0.90 | RNASE1 (0.47) | TOP2ARNASE1TYMPTK1TK2 | |
| SCHEMBL8657852 | 0.90 | RNASE1 (0.47) | TOP2ARNASE1TYMPTK1TK2 | |
| SCHEMBL6323173 | 0.90 | RNASE1 (0.51) | TOP2ARNASE1TYMPTK1TK2 | |
| SCHEMBL25764398 | 0.89 | TOP2A (0.44) | TOP2ARNASE1TK1TK2 | |
| SCHEMBL21489369 | 0.88 | RNASE1 (0.50) | RNASE1TK1TK2TYMS | |
| SCHEMBL6827418 | 0.88 | RNASE1 (0.53) | RNASE1TK1TK2TYMS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215040-A1 | METHOD AND COMPOUND | ATDBio Limited (GB) | 2025-07-03 | — | — | US | disclosed |
| WO-2023180237-A1 | METHOD AND COMPOUND | ATDBio Limited (GB) | 2023-09-28 | — | — | WO | disclosed |
| EP-4249495-A1 | METHOD FOR THE PURIFICATION OF POLYNUCLEOTIDES AND ANALOGUES THEREOF | ATDBio Limited (GB) | 2023-09-27 | — | — | EP | disclosed |
| EP-0904275-B1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | UNIV MCGILL (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-6861518-B2 | Hybrid oligonucleotide | MCGILL UNIVERSITY (CA) | 2005-03-01 | — | — | US | disclosed |
| US-20040097722-A9 | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY | 2004-05-20 | — | — | US | disclosed |
| US-20030229219-A1 | Preparation of phosphorothioate oligomers | ISIS PHARMACEUTICALS, INC. | 2003-12-11 | — | — | US | disclosed |
| US-6596857-B1 | Oligomer for use as tool in human diagnostics and therapeutics | MCGILL UNIVERSITY (CA) | 2003-07-22 | — | — | US | disclosed |
| US-20030114660-A1 | Preparation of phosphorothioate oligomers | JUST GEORGE (CA) | 2003-06-19 | — | — | US | disclosed |
| US-6476216-B1 | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 2002-11-05 | — | — | US | disclosed |
| US-6160109-A | Preparation of phosphorothioate and boranophosphate oligomers | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-12 | — | — | US | disclosed |
| US-6031092-A | Preparation of phosphorothioate oligomers | MC GILL UNIVERSITY (CA) | 2000-02-29 | — | — | US | disclosed |
| US-5945521-A | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 1999-08-31 | — | — | US | disclosed |
| EP-0904275-A1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | McGILL UNIVERSITY (CA) | 1999-03-31 | — | — | EP | disclosed |
| US-5734041-A | Preparation of chiral phosphorothioate oligomers | MCGILL UNIVERSITY (CA) | 1998-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030114660-A1 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | TOP2A 480/4885RNASE1 174/4885TYMP 15/4885 |
| US-20030229219-A1 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | TOP2A 480/4885RNASE1 174/4885TYMP 15/4885 |
| US-20250215040-A1 | METHOD AND COMPOUND | POLN, POLRMT, FBL | TOP2A 213/4885RNASE1 38/4885TYMP 56/4885 |
| US-20040097722-A9 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | TOP2A 480/4885RNASE1 174/4885TYMP 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.